- It looks at specific genetic variants that already have drugs that can target them
- Enrollment criteria is not as strict as other clinical trials in that they are taking all solid tumors based on the variant that is present.
- TAPUR does not randomly assign patients –all patients that are enrolled will receive the available drug at no cost for as long as they continue to respond
- They are already in 55 sites across 15 states, and are opening new sites regularly, many of which are in community clinics.
RESEARCH • 02/07/2017
ASCO Launches First Clinical Trial, Gives Patients Access to Treatment Based on Genomic Testing
The American Society of Clinical Oncology, more commonly known as ASCO, has flipped the traditional clinical trial model on its head, seeking to give greater access to new treatments to patients as well as understand the complex genetics involved. The clinical trial is called TAPUR, and the key difference is identifying a treatment by a patient’s tumor type, regardless of the tumor’s location. [caption id="attachment_207" align="alignright" width="215"] Dr. Laura Porter, MD, stage IV colon cancer survivor and Colon Cancer Alliance Patient Advocate Medical Consultant.[/caption] And, in an almost unprecedented show of cooperation, seven major pharmaceutical companies have agreed to participate, including: AstraZeneca, Bayer, Bristol-Myers Squibb, Eli Lilly and Company, Genentech, Merck and Pfizer. What makes this trial different?